Drugs / HiPSC-RPE cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07418177 | Feb 2026 → Jun 2028 expected | age-related macular degeneration | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HiPSC-RPE cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07418177 ↗ |
| Modality | Cell therapy | “HiPSC-RPE cells transplantation” NCT07418177 ↗ |
| Route | Other | “Subretinal transplantation of HiPSC-RPE cells” NCT07418177 ↗ |